Q3 2019 EPS Estimates for Novo Nordisk A/S (NYSE:NVO) Increased by Jefferies Financial Group

Share on StockTwits

Novo Nordisk A/S (NYSE:NVO) – Research analysts at Jefferies Financial Group lifted their Q3 2019 earnings per share (EPS) estimates for Novo Nordisk A/S in a report released on Wednesday, July 10th. Jefferies Financial Group analyst P. Welford now expects that the company will post earnings of $0.62 per share for the quarter, up from their prior estimate of $0.61. Jefferies Financial Group also issued estimates for Novo Nordisk A/S’s Q4 2019 earnings at $0.55 EPS, FY2019 earnings at $2.42 EPS, FY2020 earnings at $2.82 EPS and FY2021 earnings at $3.14 EPS.

A number of other brokerages have also recently commented on NVO. Barclays restated a “hold” rating on shares of Bank of Montreal in a report on Tuesday, June 11th. Deutsche Bank restated a “buy” rating and set a GBX 2,450 ($32.01) target price on shares of in a report on Thursday, June 20th. UBS Group cut to a “neutral” rating and lowered their target price for the company from GBX 870 ($11.37) to GBX 650 ($8.49) in a report on Wednesday, June 19th. Credit Suisse Group restated a “sell” rating and set a $6.50 target price on shares of Deutsche Bank in a report on Monday, April 29th. Finally, Pareto Securities cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Tuesday, April 30th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and five have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $112.78.

NYSE NVO opened at $47.54 on Friday. The stock has a market cap of $116.47 billion, a PE ratio of 18.87, a PEG ratio of 2.24 and a beta of 0.60. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 0.07. Novo Nordisk A/S has a twelve month low of $41.23 and a twelve month high of $52.83. The business’s fifty day simple moving average is $50.09.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Friday, May 3rd. The company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.04. The business had revenue of $4.46 billion during the quarter, compared to analysts’ expectations of $4.35 billion. Novo Nordisk A/S had a return on equity of 78.28% and a net margin of 33.60%.

Several institutional investors and hedge funds have recently made changes to their positions in NVO. Comerica Securities Inc. boosted its stake in shares of Novo Nordisk A/S by 12.0% in the 4th quarter. Comerica Securities Inc. now owns 11,443 shares of the company’s stock valued at $527,000 after buying an additional 1,223 shares during the period. Hsbc Holdings PLC boosted its stake in shares of Novo Nordisk A/S by 14.1% in the 4th quarter. Hsbc Holdings PLC now owns 5,148 shares of the company’s stock valued at $237,000 after buying an additional 637 shares during the period. Geode Capital Management LLC boosted its stake in shares of Novo Nordisk A/S by 8.3% in the 4th quarter. Geode Capital Management LLC now owns 39,942 shares of the company’s stock valued at $1,840,000 after buying an additional 3,060 shares during the period. Edmond DE Rothschild Holding S.A. boosted its stake in shares of Novo Nordisk A/S by 2.4% in the 4th quarter. Edmond DE Rothschild Holding S.A. now owns 13,702 shares of the company’s stock valued at $632,000 after buying an additional 324 shares during the period. Finally, Avalon Advisors LLC boosted its stake in shares of Novo Nordisk A/S by 494.7% in the 4th quarter. Avalon Advisors LLC now owns 422,932 shares of the company’s stock valued at $19,484,000 after buying an additional 351,810 shares during the period. Institutional investors and hedge funds own 7.15% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Further Reading: What is the Gross Domestic Product (GDP)?

Earnings History and Estimates for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.